- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Inhibrx, Eikon rise after insider buying | 1 | Seeking Alpha | ||
| Mi | H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy | 2 | Investing.com | ||
| Di | Inhibrx Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Di | Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates | 1 | Benzinga.com | ||
| Di | Inhibrx CEO says progression-free survival data leave 'no question' about OX40 agonist's durability | 2 | FierceBiotech | ||
| Di | Inhibrx cancer therapy outperforms Merck's Keytruda in mid-stage trial | 7 | Seeking Alpha | ||
| INHIBRX BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Di | Positive Studiendaten zu Krebsmedikament beflügeln Inhibrx Aktie | 1 | Investing.com Deutsch | ||
| Di | Inhibrx Biosciences, Inc.: Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study | 158 | PR Newswire | First OX40 agonist to demonstrate clinical benefit in a randomized study
INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression... ► Artikel lesen | |
| 27.08. | Citizens reiterates Market Perform on Inhibrx Biosciences stock | 2 | Investing.com | ||
| 21.08. | Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target | 1 | Investing.com | ||
| 21.08. | Stifel bekräftigt Kaufempfehlung für Inhibrx Biosciences mit Kursziel von 325 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.08. | Inhibrx Biosciences GAAP EPS of -$2.34 beats by $0.05 | 1 | Seeking Alpha | ||
| 13.08. | Inhibrx Biosciences, Inc.: Inhibrx Reports Second Quarter 2026 Financial Results | 151 | PR Newswire | SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter... ► Artikel lesen | |
| 16.07. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Inhibrx expands credit facility to $500 million with Oxford | 3 | Investing.com | ||
| 15.06. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.06. | Inhibrx BLA for ozekibart accepted by FDA | 1 | Seeking Alpha | ||
| 15.06. | FDA akzeptiert Zulassungsantrag von Inhibrx für Medikament gegen seltenen Knochenkrebs | 3 | Investing.com Deutsch | ||
| 15.06. | Inhibrx Biosciences, Inc.: Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma | 374 | PR Newswire | No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027
If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment... ► Artikel lesen | |
| 03.06. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 115,43 | 0,00 % | Can KT-621 Mark a Turning Point for Kymera Therapeutics? | ||
| TARSUS PHARMACEUTICALS | 82,77 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,670 | 0,00 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| EDGEWISE THERAPEUTICS | 43,390 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 41,620 | 0,00 % | Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress | ||
| KINIKSA PHARMACEUTICALS | 78,52 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,020 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,520 | -0,11 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| TYRA BIOSCIENCES | 22,030 | +0,09 % | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib | TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC
Favorable safety and tolerability results support chronic... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,450 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 30,500 | 0,00 % | Mineralys auf Wells Fargo Konferenz: Markteinführung von Lorundrostat nimmt Gestalt an | ||
| DYNE THERAPEUTICS | 19,190 | 0,00 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 23,830 | -0,04 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,150 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 15,700 | 0,00 % | FDA Fast Track Puts Erasca's (ERAS) Pancreatic Bet Center Stage |
Das Unternehmen INHIBRX BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 112,32 Euro und damit -0,48 % im Minus. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBRX BIOSCIENCES INC finden Sie auf Wallstreet Online.